Janssen Presents P-IIa (VEGA) PoC Study Results of Guselkumab + Golimumab for Active Ulcerative Colitis at UEG 2022
Shots:
- The P-IIa (VEGA) PoC study evaluating guselkumab + golimumab as induction therapy vs guselkumab or golimumab alone for maintenance in a ratio (1:1:1) in patients with mod. to sev. active UC
- The results showed clinical remission rate (47.9%) over guselkumab (31.0%) or golimumab alone (20.8%) @38wks.; symptomatic remission (69% vs 59.7%)
- In an exploratory analysis, endoscopic improvement, symptomatic & endoscopic remission, histologic remission, and composite histologic-endoscopic EPs were also assessed @38wks., the combination therapy followed by guselkumab/guselkumab alone/golimumab alone had AE rates (63.4%/64.8%/76.4%) & infection rates (31.0%/23.9%/31.9%), 13.1% discontinued treatment before a final dose of the study intervention
Ref: PRNewswire | Image: Janssen
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.